Results: 19

Effectiveness of treatment of exudative age-related macular degeneration with anti-vascular endothelial growth factor drugs

Rev. bras. oftalmol; 83 (), 2024
ABSTRACT Objective: To characterize the effectiveness of anti-vascular endothelial growth factor drugs in exudative age-related macular degeneration. Methods: Retrospective longitudinal study of 54 patients with age-related macular degeneration receiving bevacizumab or aflibercept. Demographic data, vi...

Terapia fotodinâmica com verteporfina associada à injeção intravítrea de antifator de crescimento endotelial vascular para tratamento de hemangioma circunscrito de coroide

Rev. bras. oftalmol; 81 (), 2022
RESUMO O hemangioma de coroide é um tumor vascular benigno, de coloração vermelho-alaranjada, bem delimitado, caracterizado por uma placa elevada. É um tumor raro, com prevalência de um caso a cada 40 tumores de coroide. O diagnóstico pode ser feito por meio da clínica associada à avaliação bio...

Profiles of endoglin and vascular endothelial growth factor based on staging and histological grading of colorectal cancer and their relationship with bevacizumab therapy

Objective: The present study evaluated the profile of endoglin (CD105) and vascular endothelial growth factor (VEGF) based on staging and histopathological grading of colorectal cancer as well as their relationship with bevacizumab therapy. Methods: A total of 88 cases of colorectal adenocarcinoma were ...

Age-related macular degeneration: a review of current therapies and new treatments

Arq. bras. oftalmol; 83 (6), 2020
ABSTRACT Age-related macular degeneration is the leading cause of vision loss in elderly individuals, as well as a medical and socio-economic challenge. The treatment of dry age-related macular degeneration is based on vitamin supplementation. New treatment studies are focused on preventing the progressi...

Three versus five intravitreal aflibercept injections as the initial loading phase in the treatment of diabetic macular edema: one-year results

Arq. bras. oftalmol; 83 (5), 2020
ABSTRACT Purpose: To compare the efficacy of three initial monthly intravitreal aflibercept injections followed by pro re nata (3+PRN) dosing versus five initial monthly intravitreal aflibercept injections followed by pro re nata (5+PRN) dosing in patients with diabetic macular edema. Methods: A total ...

Survey among retina specialists in Brazil about inflammatory reactions after intravitreal antiangiogenic therapy

Arq. bras. oftalmol; 83 (3), 2020
ABSTRACT Purpose: This survey aimed at assessing the clinical characteristics of patients with inflammatory reactions after intravitreal injection of antiangiogenic agents and the techniques employed by Brazilian retina specialists. Methods: We sent an 18-item questionnaire electronically to retina spe...

Do not allow protocols to obliterate your art of treating

Rev. bras. oftalmol; 78 (6), 2019

Mecanismo sensor y de adaptación a los niveles de oxígeno y su implicancia en las enfermedades cardiovasculares: a propósito del Premio Nobel de Fisiología-Medicina 2019

Rev. chil. cardiol; 38 (3), 2019
RESUMEN: El Premio Nobel 2019 en Fisiología-Medicina se confirió a los Profesores Gregg Semenza, William Kaelin y Sir Peter Ratcliffe por sus investigaciones en la maquinaria molecular que regula la expresión de genes sensibles a los cambios en los niveles de oxígeno. La síntesis de eritropoyetina i...

Impacto orçamentário da incorporação de medicamentos para tratamento em segunda linha do edema macular diabético no SUS sob a perspectiva da Secretaria de Estado de Saúde de Minas Gerais, Brasil

Resumo: Os objetivos foram efetuar a análise do impacto orçamentário para a incorporação de segunda linha terapêutica com terapia antiangiogênica de aplicação intravítrea, para tratamento de edema macular diabético, no âmbito do Sistema Único de Saúde (SUS) em Minas Gerais, Brasil, discutin...

Aflibercept versus dexametasona en edema macular secundario a la oclusión de la vena central de la retina

Medwave; 19 (11), 2019
INTRODUCCIÓN El edema macular es una complicación frecuente de la oclusión de la vena central de la retina que clínicamente provoca deterioro de la agudeza visual. Los tratamientos más utilizados son el implante de dexametasona y los fármacos anti factor del crecimiento endotelial vascular, destaca...